Adverse events: any · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether benzodiazepines changes adverse events: any compared with phenobarbital (as active placebo) (very low certainty).
1 finding from 1 review
Adverse events: any · patients with schizophrenia
1 finding from 1 review
Intervention not reported
Adverse events: Any event · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
The intervention showed no clear difference in adverse events: Any event (moderate certainty).
1 finding from 1 review
Adverse effects: Any adverse events · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether CHOLINERGIC DRUGS changes adverse effects: Any adverse events compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse events experienced at short or long term ‐ general adverse events 24 weeks' · patients with schizophrenia
It is very uncertain whether COMPARISON 1: CBT+ STANDARD CARE changes adverse events: General: any adverse event compared with STANDARD CARE ALONE (very low certainty).
1 finding from 1 review
Adverse events: Any prolactin‐related ‐ medium term · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: Any prolactin‐related ‐ medium term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).
1 finding from 1 review
Adverse events: Any glucose‐related ‐ medium/long term · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: Any glucose‐related ‐ medium/long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: any adverse events requiring hospitalisation · people with primary delusional infestation
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Adverse events: Movement disorder ‐ any extra pyramidal symptom · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptom compared with ORAL QUETIAPINE (low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
Other adverse events: any serious adverse event ‐ short and long term · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes other adverse events: any serious adverse event ‐ short and long term compared with ANY ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐ short term · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐… compared with ORAL RISPERIDONE (moderate certainty).
1 finding from 1 review
Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term · patients with schizophrenia
1 finding from 1 review
Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term · patients with schizophrenia
1 finding from 1 review
Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term Spontaneous reporting by study participants · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: General: Severe adverse event ‐ any dose risperidone… compared with PLACEBO (very low certainty).
1 finding from 1 review